Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 6/20 | 0.57 |
| ▸ | NPY1R | P25929 | 5/20 | 0.57 |
| ▸ | NPY2R | P49146 | 3/20 | 0.57 |
| ▸ | BACE1 | P56817 | 5/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575832 | 0.96 | NPY4R (0.60) | NPY4RNPY1RNPY2RFOLH1NPY5R | |
| SCHEMBL30317543 | 0.92 | NPY4R (0.60) | NPY4RNPY1RNPY2RFOLH1NPY5R | |
| SCHEMBL30900768 | 0.92 | OPRD1 (0.54) | NPY4RNPY1RNPY2ROPRD1 | |
| SCHEMBL30473782 | 0.90 | NPY4R (0.59) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL30714766 | 0.89 | OPRD1 (0.57) | NPY4RNPY1RNPY2RBACE1FOLH1 | |
| SCHEMBL29531691 | 0.89 | NPY4R (0.59) | NPY4RNPY1RNPY2RBACE1FOLH1 | |
| SCHEMBL31256952 | 0.88 | NPY1R (0.56) | NPY4RNPY1RNPY2RBACE1FOLH1 | |
| SCHEMBL2184740 | 0.88 | NPY4R (0.66) | NPY4RNPY1RNPY2RBACE1FOLH1 | |
| SCHEMBL30061881 | 0.88 | NPY4R (0.63) | NPY4RNPY1RNPY2RBACE1FOLH1 | |
| SCHEMBL30544311 | 0.87 | LTA4H (0.62) | BACE1BACE2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034167-A1 | HYALURONIC ACID-BASED HYDROGELS FOR JOINT THERAPY | US GOV VETERANS AFFAIRS (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034167-A1 | HYALURONIC ACID-BASED HYDROGELS FOR JOINT THERAPY | COL1A1, COL2A1, COL14A1 | NPY4R 86/4885NPY1R 38/4885NPY2R 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.